The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Neuropsychological Tests

Neuropsychological Tests

Neuropsychological Tests are standardized assessments used to evaluate cognitive, behavioral, and emotional functioning.
These tests measure various aspects of brain-behavior relationships, such as intelligence, memory, attention, language, and executive function.
They are commonly used in the diagnosis and management of neurological, psychiatric, and developmental disorders.
Neuropsychological Tests provide valuable insights into an individual's strengths, weaknesses, and cognitive profile, aiding in treatment planning and monitoring.
These assessments are typically administered by trained professionals, such as neuropsychologists or psychologists, and the results are interpreted in the context of the individual's medical history and other relevant factors.
Accurate and reproducible neuropsychological assessments are essential for effective clinical decision-making and improving patient outcomes.

Most cited protocols related to «Neuropsychological Tests»

Cognitive domain and test selection were based on a combination of methods evolving from regular meetings of the CTF. A subcommittee was formed to specifically undertake the design of the neuropsychological test battery, to bring essential issues to the larger group and to interface with the ADCs. Three overriding criteria governed decisions for selecting domains and tests. The first was the mandate for the UDS to initially focus on cognitive markers of aging and of dementia associated with AD, the second was to minimize burden on the ADCs and their subjects, and the third was to accommodate the continuity of measures that ADCs have previously collected. A fourth principle that emerged after an initial set of domains and tests was identified was the need to overlap with other ADC initiatives such as the Late Onset Alzheimer’s Disease (LOAD) Genetics study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Because of the need to focus on the cognitive continuum from aging without dementia, to MCI, to AD, cognitive domains were selected for their sensitivity to age-related change in cognition [17 (link)–29 (link)] sensitivity to the demonstrated primary cognitive impairments in AD [30 –36 (link)], ability to measure change over time and to stage AD [37 (link)], and ability to predict progression from MCI to AD [38 (link)–41 ]. Additional criteria for test selection included applicability of the measures to different educational levels, to diverse racial/ethnic minority groups and to Spanish-speaking populations. A Spanish translation of the UDS has been completed and is available on the NACC website (https://www.alz.washington.edu).
The minimization of burden, an issue of feasibility, had to figure centrally in test selection. Many ADCs have been conducting research for over 20 years. Well-established protocols and longitudinal research projects could be disrupted by the need to significantly alter assessment and enrollment methods, notwithstanding the added time burden for subjects and their study partners. Thus, with input from the ADCs, the CTF concluded that the neuropsychological battery should not add more than 30 minutes to existing protocols at each Center. One implication of this principle was that tests already in use by all or most ADCs would be high on the list of candidates for inclusion.
The CTF conducted several surveys of the ADCs to gather data about their ongoing assessment practices including, among other variables: 1) cognitive domains tested; 2) specific instruments and versions, for tests with multiple forms; 3) populations of subjects followed (i.e., disease and control groups; clinic and/or community samples); 4) frequency of subject visits. Once these data were acquired, the most commonly tested domains and the most commonly used specific measures were identified and comments and approval were solicited from the ADCs.
Publication 2009
Cognition Disease Progression Disorders, Cognitive Ethnic Minorities Hispanic or Latino Hypersensitivity Neuropsychological Tests Population Group Presenile Dementia Racial Groups SET Domain
Archival data were reviewed from 4248 consecutive participants recruited into the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and Alzheimer's Disease Patient Registry (ADPR) database. The Rochester Mayo ADPR is responsible for recruiting dementia patients and non-demented control subjects for studies on the progression of Alzheimer's disease through the Department of Community and Internal Medicine and does not operate in Jacksonville. The Rochester and Jacksonville ADRC sites acquire dementia patients from Behavioral Neurology. The Jacksonville ADRC site also recruits community controls via churches and community agencies. The same inclusion/exclusion criteria are applied for normal controls across both recruitment sites and has been published extensively through analyses of the MOANS16 (link)-19 and MOAANS20 (link)-22 (link) data. Patients with memory concerns raised by either the patient themselves, a family member, or a physician undergo a comprehensive neurological evaluation and neuropsychological testing to confirm or rule out dementia and Alzheimer disease.
A total of 1141 individuals with 16 or more self-reported years of education were identified. The sample included 1064 (93%) individuals who self-identified as Caucasian and 77 (7%) who self-identified as African-American. Of the 1141 participants, 658 individuals (242 males and 416 females) had no dementia and were considered cognitively normal (see Ivnik et al.19 for full criteria used to define normal cognition). The remaining 307 (164 males and 143 females) carried diagnoses of dementia established via consensus among ADRC investigators and based on published diagnostic criteria. Diagnoses included 202 (66%) patients with probable Alzheimer's disease, 48 (16%) with dementia with Lewy bodies, 18 (6%) with frontotemporal dementia, 13 (4%) with vascular dementia, and 25 (8%) with other dementia etiologies. A sample of 176 patients (106 males and 70 females) diagnosed with Mild Cognitive Impairment (MCI) was also included for comparison purposes.
The total sample included 512 (45%) males and 629 (55%) females, with a mean age of 75.9 (SD=7.2) years and a mean self-reported education of 17.1 (SD=1.5) years. There were no significant between-group differences (dementia vs. no dementia) in terms of age, gender, or education.
While the MMSE was available in diagnostic meetings, the diagnosis of dementia (and particular subtype) was arrived at via consensus-based judgment taking into account information from the neurological examination, clinical interview, lab results, imaging, informant ratings of activities of daily living (ADLs), as well as neuropsychological test data. Therefore, the MMSE had minimal impact on diagnostic decisions in the dementia cohort and was not considered at all as part of the determination of control status.
Publication 2008
African American Alzheimer's Disease Caucasoid Races Cognition Cognitive Impairments, Mild Dementia, Vascular Diagnosis Disease Progression Family Member Females Lewy Body Disease Males Memory Mini Mental State Examination Neurologic Examination Neuropsychological Tests Patients Physicians Pick Disease of the Brain Presenile Dementia
Participants in this study included 93 patients with AD and 43 patients with amnestic MCI (aMCI) who were recruited from the Memory Disorder Clinic at the Samsung Medical Center in Seoul, Korea from November 2005 to January 2007. All patients with AD met the criteria for probable AD proposed by the National Institute of Neurological and Communicative Diseases and Stroke and Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) (3 (link)). The aMCI patients were diagnosed according to the criteria proposed by Peterson et al. (4 (link)): 1) subjective memory complaint as described by the patient and/or caregiver, 2) normal general cognitive function, as defined by a score of 24 or greater on the Korean version of Mini-Mental State Examination (MMSE), 3) ability to participate in normal activities of daily living (ADL), judged clinically and by an ADL scale, 4) objective memory decline below the 16th percentile on neuropsychological tests, and 5) non-conformance to clinical criteria for diagnosis of dementia.
All patients underwent a comprehensive evaluation consisting of a detailed medical history, neurological examinations, and a neuropsychological evaluation (SNSB). Additionally, laboratory tests were used to confirm that there were no secondary causes for dementia or cognitive impairment. Magnetic Resonance Imaging (MRI) was performed on all patients, and all patients with structural brain lesions or severe white matter ischemia (caps or band >10 mm and deep white lesion >25 mm) were excluded. Patients who were illiterate were also excluded, regardless of formal education status.
The normal control (NC) group consisted of 77 healthy spouses or caregivers of patients from the memory disorder clinic. All controls were screened for neurological and psychiatric illnesses, and those who were identified to have any of these illnesses were excluded from the study. All subjects in the NC group met the criteria for healthy controls proposed by Christensen et al. (5 ) and did not have dementia as defined by the score below 8 points on the Korean Dementia Screening Questionnaire (KDSQ) (6 ) as well as by an ADL score less than 8 on Seoul Instrumental Activities of Daily Living (S-IADL) (7 ).
The three groups included in this study did not differ significantly in age, education level, and gender. In terms of Clinical Dementia Rating (CDR) scores (8 (link)), all participants in the NC group had a CDR score of 0; all patients in the MCI group had a CDR score of 0.5; and of the participants in the AD group 35 had a CDR score of 0.5 (mild stage, 38%), 42 had a CDR score of 1 (mild to moderate stage, 45%), and 16 had a CDR score of 2 (moderate stage, 17%). Among patients with AD, the CDR groups did not differ in age, education level, and gender. We obtained informed consents from all the patients and controls, and this study was approved by the Institutional Review Board of Samsung Medical Center (2005-02-008).
Publication 2010
Alzheimer's Disease Brain Cerebrovascular Accident Cognition Communicative Disorders Diagnosis Disorders, Cognitive Ethics Committees, Research Gender Ischemia Koreans Memory Memory Disorders Mental Disorders Mini Mental State Examination Neurologic Examination Neuropsychological Tests Patients Presenile Dementia White Matter
All participants had normal or corrected vision, no history of neurological, psychiatric, or vascular disease, and were not taking any psychotropic or hypertension medications. In addition, they were considered ‘non-gamers’ given that they played less than 2 hours of any type of video game per month. For NeuroRacer, each participant used their left thumb for tracking and their right index finger for responding to signs on a Logitech (Logitech, USA) gamepad controller. Participants engaged in three 3-minute runs of each condition in a randomized fashion. Signs were randomly presented in the same position over the fixation cross for 400 msec every 2, 2.5, or 3 seconds, with the speed of driving dissociated from sign presentation parameters. The multitasking cost index was calculated as follows: [(‘Sign & Drive’ performance - ‘Sign Only’ performance) / ‘Sign Only’ performance] * 100. EEG data for 1 MTT Post-training participant and 1 STT Pre-training participant were corrupted during acquisition. 2 MTT participants, 2 STT participants, and 4 NCC participants were unable to return to complete their 6-month follow-up assessments. Critically, no between-group differences were observed for neuropsychological assessments (p= .52) or Pre-training data involving: i) NeuroRacer thresholding for both Road (p= .57) and Sign (p= .43), ii) NeuroRacer component task performance (p> .10 for each task), iii) NeuroRacer multitasking costs (p= .63), iv) any of the cognitive tests (all ANOVAs at Pre-training: p≥ .26), v) ERSP power for either condition (p≥ .12), and, vi) coherence for either condition (p≥ .54).
Publication 2013
Cognitive Testing Crossing Over, Genetic Fingers High Blood Pressures N-(4-hydroxyphenethyl)cotinine carboxamide Neoplasm Metastasis neuro-oncological ventral antigen 2, human Neuropsychological Tests Pharmaceutical Preparations Psychotropic Drugs Task Performance Thumb Vascular Diseases Vision
All participants had normal or corrected vision, no history of neurological, psychiatric, or vascular disease, and were not taking any psychotropic or hypertension medications. In addition, they were considered ‘non-gamers’ given that they played less than 2 hours of any type of video game per month. For NeuroRacer, each participant used their left thumb for tracking and their right index finger for responding to signs on a Logitech (Logitech, USA) gamepad controller. Participants engaged in three 3-minute runs of each condition in a randomized fashion. Signs were randomly presented in the same position over the fixation cross for 400 msec every 2, 2.5, or 3 seconds, with the speed of driving dissociated from sign presentation parameters. The multitasking cost index was calculated as follows: [(‘Sign & Drive’ performance - ‘Sign Only’ performance) / ‘Sign Only’ performance] * 100. EEG data for 1 MTT Post-training participant and 1 STT Pre-training participant were corrupted during acquisition. 2 MTT participants, 2 STT participants, and 4 NCC participants were unable to return to complete their 6-month follow-up assessments. Critically, no between-group differences were observed for neuropsychological assessments (p= .52) or Pre-training data involving: i) NeuroRacer thresholding for both Road (p= .57) and Sign (p= .43), ii) NeuroRacer component task performance (p> .10 for each task), iii) NeuroRacer multitasking costs (p= .63), iv) any of the cognitive tests (all ANOVAs at Pre-training: p≥ .26), v) ERSP power for either condition (p≥ .12), and, vi) coherence for either condition (p≥ .54).
Publication 2013
Cognitive Testing Crossing Over, Genetic Fingers High Blood Pressures N-(4-hydroxyphenethyl)cotinine carboxamide Neoplasm Metastasis neuro-oncological ventral antigen 2, human Neuropsychological Tests Pharmaceutical Preparations Psychotropic Drugs Task Performance Thumb Vascular Diseases Vision

Most recents protocols related to «Neuropsychological Tests»

All patients are assessed with a ~ 1-h neuropsychological test battery, including ‘cold’ (emotion-independent) cognitive tasks indexing reaction time; psychomotor speed; verbal learning and memory; working memory; and executive functions, as well as ‘hot’ (emotion-dependent) cognitive tasks from the Danish version of the EMOTICOM test-battery indexing emotion recognition; emotion detection; and moral emotions in social situations [60 (link)].
Patients in subcohorts I-II will complete an additional ~ 1 h of testing with tasks assessing mental flexibility, verbal fluency, and visuospatial learning and memory (see Additional questionnaires for the subcohort I-II only are in bold.
Table 3 for a complete overview of all cognitive tasks). In addition, patients’ subjective experiences of cognitive disturbances will be assessed by the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) questionnaire [36 (link)].

Cognitive testing before treatment

Cognitive TestCognitive Domaine
Whole Cohort
 Simple Reaction Time task (SRT)Reaction time
 Trail Making Test A & BPsychomotor speed/executive function
 Symbol Digit Modality Task (SDMT)Psychomotor speed/working memory
 Letter-Number Sequence (LNS)Working memory
 D-KEFS Color-Word Interference Test (Stroop)Executive function
 Rey Auditory Verbal Learning Test (RAVLT)Learning/memory
 EMOTICOM Emotional Recognition Task (ERT)Emotion recognition accuracy
 EMOTICOM Emotional Intensity Morphing Task (IMT)Emotion perceptual detection threshold
 EMOITCOM Moral Emotions Task (MET)Social cognition: guilt and shame
Additional testing in the subcohorts
 D-KEFS Verbal FluencyExecutive function
 Rey Complex Figure Test (RCFT)Visuo-spatial learning/memory
 Probabilistic Reversal Learning taskLearning within a feedback context
 Screen for Cognitive Impairments in Psychiatry—Depression (SCIP-D)Memory, working memory, vocabulary, psychomotor speed
Patients in subcohorts I-II will complete an additional ~ 1 h of testing with tasks assessing mental flexibility, verbal fluency, and visuospatial learning and memory (see Additional questionnaires for the subcohort I-II only are in bold.
Full text: Click here
Publication 2023
Cognition Cognitive Testing Common Cold Disorders, Cognitive Emotions Executive Function Fingers Guilt Memory Memory, Short-Term Morphine Neuropsychological Tests Patients Recognition, Psychology
The BIODEGMAR cohort is an observational longitudinal study that enrolls patients with neurodegenerative diseases visiting the Cognitive Decline and Movement Disorders Unit of Hospital del Mar (Barcelona, Spain). The procedures of the BIODEGMAR study include extensive neuropsychological evaluation, MRI, APOE ε4 genotyping, lumbar puncture for CSF collection and blood sampling. Clinical evaluation was performed by a neurologist, including anamnesis, physical examination and clinical diagnosis. Neuropsychological evaluation was performed by a neuropsychologist and consisted of a series of standardized cognitive tests and functional scales. A comprehensive description of the BIODEGMAR cohort has been previously published, with further details on the inclusion and exclusion criteria and on core AD CSF biomarker procedures, including assay details and cutoff determination [31 , 32 ]. In this study, 175 patients of the BIODEGMAR cohort were included from 27 April 2017 to 24 July 2020. The clinical diagnoses included SCD (n=18, similar diagnostic criteria as for Paris cohort), MCI (n=74) and, for subjects with moderate to severe cognitive impairment, possible AD dementia (n=11), probable AD dementia (n=43), LBD (n=2), extrapyramidal syndrome (n=2), vascular cognitive impairment and dementia (VCID; n=4), progressive supranuclear palsy (PSP; n=2), corticobasal syndrome (n=4), behavioral variant of FTD (bvFTD; n=4), primary progressive aphasia (PPA; n=8) and cerebral amyloid angiopathy (CAA; n=3).
Full text: Click here
Publication 2023
ApoE protein, human Biological Assay Biological Markers Blood Vessel Cerebral Amyloid Angiopathy Cognitive Testing Corticobasal Degeneration Dementia Diagnosis Disorders, Cognitive Extrapyramidal Disorders Immunologic Memory Movement Disorders Neurodegenerative Disorders Neurologists Neuropsychological Tests Patients Physical Examination Progressive Supranuclear Palsy Punctures, Lumbar
Paris cohort enrolled a total of 212 patients who had undergone CSF analysis at the Centre of Cognitive Neurology at Lariboisière Fernand-Widal University Hospital between March 2014 and December 2019, including participants with subjective cognitive decline (SCD, n=21), non-AD mild cognitive impairment (non-AD MCI, n=45), AD-MCI (n=40), AD dementia (n=75) and non-AD dementia (n=31). Non-AD dementia patients encompassed patients with dementia with Lewy bodies (DLB, n=12), frontotemporal dementia (FTD, n=15), vascular cognitive impairment and dementia (VCID, n=3) and Creutzfeldt Jakob disease (n=1). Patients underwent a thorough clinical examination involving personal medical and family histories, treatment, neurological examination, extensive neuropsychological assessment, APOE genotyping, brain magnetic resonance imaging (MRI) extensive neuropsychological evaluation, MRI, APOE genotyping, blood and CSF analysis and fluid sampling for collection (blood and CSF). The diagnosis for each patient was made during multidisciplinary consensus meetings (including neurologists, neuropsychologists, gerontologists, neuroradiologist and biochemists) considering results of validated CSF biomarkers and according to clinical diagnostic criteria for AD dementia [3 (link)], MCI due to AD (AD-MCI) [26 (link)], DLB [27 (link)] and FTD [28 (link)]. AD patients displayed CSF biomarkers on the AD continuum [3 (link)]. MCI of other causes (non-AD MCI) included patients with psychiatric disorder, sleep apnea, or systemic disease. Non-AD MCI presented with normal CSF biomarkers or suspected non-Alzheimer pathophysiology (normal Aβ1-42/40, high p-tau and/or high t-tau). Included SCD participants were individuals with several years of clinical follow-up for a clinical complaint, presenting with normal cognitive testing and no abnormalities at imaging and CSF examinations [29 (link), 30 (link)].
Full text: Click here
Publication 2023
ApoE protein, human Biological Markers BLOOD Blood Vessel Brain Central Nervous System Cognition Congenital Abnormality Diagnosis Disease, Creutzfeldt-Jakob Disorders, Cognitive Geriatricians Lewy Bodies Mental Disorders Neurologic Examination Neurologists Neuropsychological Tests Patients Physical Examination Pick Disease of the Brain Presenile Dementia Sleep Apnea Syndromes
Cognitive functions were assessed using the Wechsler Memory Scale – Revised (WMS-R) [12 ]. The test was administered during a routine visit to the general practitioner and it required around 1 h to complete. The WMS-R is a neuropsychological test designed to measure different memory functions such as verbal, visual memory, attention/concentration and delayed memory. The psychometric characteristics of the WMS-R are evaluated and related to its clinical utility in the Romanian population [13 , 14 (link)]. The weighted scores (weighted raw score summaries) were calculated according to the scoring system from in the WMS-R administrative and scoring manual, with a higher score indicating better functioning.
Full text: Click here
Publication 2023
Attention Cognition Delayed Memory Memory Neuropsychological Tests Psychometrics Vision
Participants were drawn from the WRAP, a longitudinal study designed to identify midlife factors associated with the development of Alzheimer’s disease.39 (link),40 (link) Enrolment of participants began in 2001, with the first follow-up visit occurring 2 to 4 years after the baseline visit and all additional visits occurring at 2-year intervals thereafter. WRAP participants were free of dementia at enrolment (mean age 54 years). All study procedures were approved by the University of Wisconsin School of Medicine and Public Health Institutional Review Board and are in concordance with the Declaration of Helsinki.
At each study visit, participants completed comprehensive neuropsychological assessment and multiple questionnaires related to a broad array of factors, including lifestyle, modifiable risk factors, medical history and memory functioning. Sleep measures were added in two stages to the WRAP assessment protocol. To be eligible for the primary analyses, participants needed to have completed the full set of sleep measures at least once and be free of dementia at time of sleep assessment (n = 619). To be eligible for secondary analyses, participants needed to have completed at least one of the sleep questionnaires described below and had completed a Pittsburgh Compound B (PiB) PET scan.
Full text: Click here
Publication 2023
Developmental Disabilities Ethics Committees, Research factor A Neuropsychological Tests Pittsburgh compound B Positron-Emission Tomography Presenile Dementia Sleep

Top products related to «Neuropsychological Tests»

Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium, China, Italy, India, Israel, France, Spain, Denmark, Canada, Hong Kong, Poland, Australia
SPSS is a software package used for statistical analysis. It provides a graphical user interface for data manipulation, statistical analysis, and visualization. SPSS offers a wide range of statistical techniques, including regression analysis, factor analysis, and time series analysis.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in United States, United Kingdom, Germany, Japan, Denmark, China, Belgium, Poland, Austria, Australia
SPSS 20.0 is a statistical software package developed by IBM for data analysis, data management, and data visualization. It provides a wide range of statistical techniques, including descriptive statistics, bivariate statistics, prediction for numerical outcomes, and prediction for identifying groups. SPSS 20.0 is designed to help users analyze and understand data quickly and efficiently.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
Sourced in United States, United Kingdom, Japan, Austria, Germany, Denmark, Czechia, Belgium, Sweden, New Zealand, Spain
SPSS version 25 is a statistical software package developed by IBM. It is designed to analyze and manage data, providing users with a wide range of statistical analysis tools and techniques. The software is widely used in various fields, including academia, research, and business, for data processing, analysis, and reporting purposes.
Sourced in United States, United Kingdom, Germany, Canada, Japan, Sweden, Austria, Morocco, Switzerland, Australia, Belgium, Italy, Netherlands, China, France, Denmark, Norway, Hungary, Malaysia, Israel, Finland, Spain
MATLAB is a high-performance programming language and numerical computing environment used for scientific and engineering calculations, data analysis, and visualization. It provides a comprehensive set of tools for solving complex mathematical and computational problems.
Sourced in United States, United Kingdom, Japan, Germany
SPSS is a software package used for statistical analysis. It provides a graphical user interface and a robust set of tools for data manipulation, analysis, and visualization. SPSS is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, factor analysis, and time series analysis.
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
Sourced in United States, Japan, Germany, United Kingdom, Austria, Poland, Belgium
SPSS Statistics 21 is a software package used for statistical analysis. It provides a comprehensive set of tools for data management, analysis, and visualization. The software is designed to handle a wide range of data types and can be used for a variety of statistical techniques, including regression analysis, hypothesis testing, and multivariate analysis.
Sourced in United States, United Kingdom, Japan, Austria, Germany, Belgium, Israel, Hong Kong, India
SPSS version 23 is a statistical software package developed by IBM. It provides tools for data analysis, data management, and data visualization. The core function of SPSS is to assist users in analyzing and interpreting data through various statistical techniques.

More about "Neuropsychological Tests"

Neuropsychological Assessments, Cognitive Evaluations, Brain-Behavior Relationship Tests, Intelligence Tests, Memory Assessments, Attention Measures, Language Evaluations, Executive Function Exams, Psychological Examinations, Psychometric Assessments, SPSS Software, SAS 9.4, SPSS 20.0, SPSS version 20, SPSS version 25, MATLAB, SPSS version, SPSS version 22.0, SPSS Statistics 21, SPSS version 23.
Neuropsychological tests are standardized tools used to evaluate an individual's cognitive, behavioral, and emotional functioning.
These assessments measure various aspects of brain-behavior relationships, such as intelligence, memory, attention, language, and executive function.
They are commonly employed in the diagnosis and management of neurological, psychiatric, and developmental disorders, providing valuable insights into a person's strengths, weaknesses, and cognitive profile.
These tests are typically administered by trained professionals, such as neuropsychologists or psychologists, and the results are interpreted within the context of the individual's medical history and other relevant factors.
Accurate and reproducible neuropsychological assessments are essential for effective clinical decision-making and improving patient outcomes.
PubCompare.ai, an AI-driven research platform, can enhance the accuracy and reproducibility of these tests by optimizing research protocols and helping identify the best protocols from literature, pre-prints, and patents.
By utilizing advanced AI-powered comparisons, PubCompare.ai can assist in locating the optimal protocols and products for your neuropsychological assessment needs, leading to improved test results and better patient care.